Preclinical studies also correlated TIM-3 upregulation to a resistance to anti-PD-1 therapy, and elevated VISTA expression was observed in patients with melanoma who underwent disease progression while receiving anti-PD-1 inhibitor therapy [119]. The gene discussed is HAVCR2; the disease is melanoma.